{"id":20592,"date":"2023-11-06T15:06:32","date_gmt":"2023-11-06T15:06:32","guid":{"rendered":"https:\/\/kraios.app\/news\/saglik\/2023\/11\/06\/biontech-kovid-19-asisi-satislarinin-azalmasiyla-2023-gelir-tahminini-4-milyar-avroya-dusurdu\/"},"modified":"2023-11-06T15:06:32","modified_gmt":"2023-11-06T15:06:32","slug":"biontech-kovid-19-asisi-satislarinin-azalmasiyla-2023-gelir-tahminini-4-milyar-avroya-dusurdu","status":"publish","type":"post","link":"https:\/\/kraios.app\/news\/saglik\/2023\/11\/06\/biontech-kovid-19-asisi-satislarinin-azalmasiyla-2023-gelir-tahminini-4-milyar-avroya-dusurdu\/","title":{"rendered":"BioNTech, Kovid-19 a\u015f\u0131s\u0131 sat\u0131\u015flar\u0131n\u0131n azalmas\u0131yla 2023 gelir tahminini 4 milyar avroya d\u00fc\u015f\u00fcrd\u00fc"},"content":{"rendered":"<p><\/p>\n<div>\n<p>BioNTech, 2023&#8217;\u00fcn \u00fc\u00e7\u00fcnc\u00fc \u00e7eyre\u011fine ili\u015fkin finansal sonu\u00e7lar\u0131n\u0131 a\u00e7\u0131klad\u0131.<\/p>\n<p>Buna g\u00f6re \u015firketin \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrekteki net kar\u0131, ge\u00e7en y\u0131l\u0131n ayn\u0131 d\u00f6nemine k\u0131yasla y\u00fczde 91 d\u00fc\u015ferek 160,6 milyon avroya geriledi. BioNTech, ge\u00e7en y\u0131l\u0131n temmuz-eyl\u00fcl d\u00f6neminde 1 milyar 784 milyon avro kar a\u00e7\u0131klam\u0131\u015ft\u0131.<\/p>\n<p>BioNTech\u2019in ABD&#8217;li orta\u011f\u0131 Pfizer veya ABD&#8217;li rakibi Moderna&#8217;n\u0131n aksine \u00fc\u00e7\u00fcnc\u00fc \u00e7eyre\u011fin sonunda kar a\u00e7\u0131klamas\u0131 dikkati \u00e7ekti.<\/p>\n<p>\u015eirketin gelirleri, \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrekte 2022&#8217;nin ayn\u0131 d\u00f6nemine g\u00f6re y\u00fczde 74\u2019ten fazla azalarak 895,3 milyon avroya indi. BioNTech, ge\u00e7en y\u0131l\u0131n \u00fc\u00e7\u00fcnc\u00fc \u00e7eyre\u011finde 3 milyar 461,2 milyon avro gelir elde etmi\u015fti.<\/p>\n<p>BioNTech Mali \u0130\u015fler M\u00fcd\u00fcr\u00fc (CFO) Jens Holstein, BioNTech&#8217;in \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrekte kar a\u00e7\u0131klayabilmesinin temel nedeninin Pfizer ve di\u011fer \u015firketlerle kurulan, kar ve maliyetlerin payla\u015f\u0131ld\u0131\u011f\u0131 ortakl\u0131k modeli oldu\u011funu belirtti.<\/p>\n<p>Holstein, &#8220;B\u00fcy\u00fck ila\u00e7 \u015firketleriyle olan stratejik i\u015fbirli\u011fi modelimiz, ila\u00e7lar\u0131 geli\u015ftirmemize ve geni\u015f \u00e7apta ticarile\u015ftirmemize yard\u0131mc\u0131 olurken bize ek finansal esneklik sa\u011fl\u0131yor.&#8221; dedi.<\/p>\n<p>\u015eirketin Ocak-Eyl\u00fcl 2023&#8217;teki gelirleri 7,15 milyar avro ve net kar\u0131 da 472,4 milyon avro olarak a\u00e7\u0131kland\u0131.<\/p>\n<p>Kovid-19 a\u015f\u0131s\u0131 sat\u0131\u015flar\u0131ndaki azal\u0131\u015f nedeniyle daha \u00f6nce 5 milyar avro olan y\u0131ll\u0131k bazda gelir beklentisi 4 milyar avroya d\u00fc\u015f\u00fcr\u00fcld\u00fc. \u015eirket, ge\u00e7en y\u0131l b\u00fcy\u00fck \u00e7o\u011funlu\u011fu Kovid-19 a\u015f\u0131s\u0131 sat\u0131\u015f\u0131ndan olmak \u00fczere 17,2 milyar avro gelir elde etmi\u015fti.<\/p>\n<p>mRNA teknolojisiyle Kovid-19 a\u015f\u0131s\u0131n\u0131 ilk piyasaya s\u00fcren BioNTech, anti-kanser ila\u00e7lar\u0131na odaklan\u0131yor. Akci\u011fer kanserine kar\u015f\u0131 &#8220;BNT316&#8221; adl\u0131 ila\u00e7 aday\u0131na y\u00f6nelik faz 3 \u00e7al\u0131\u015fmas\u0131, Haziran 2023\u2019ten beri y\u00fcr\u00fct\u00fcl\u00fcyor. BioNTech, ayn\u0131 zamanda antikor-ila\u00e7 konjugatlar\u0131 (ADC) olarak adland\u0131r\u0131lan ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerine dayal\u0131 tedaviler \u00fczerinde de \u00e7al\u0131\u015fmalar yap\u0131yor. Bu teknolojinin kemoterapinin yerini alma potansiyelinin oldu\u011fu belirtiliyor.<\/p>\n<p>\u00d6te yandan \u015firket, gelir beklentilerinin azalmas\u0131yla 2023 AR-GE b\u00fct\u00e7esini ikinci kez d\u00fc\u015f\u00fcrerek 2 ila 2,2 milyar avrodan 1,8 ila 2 milyar avro aral\u0131\u011f\u0131na revize etti.<\/p>\n<p>                            <span class=\"detay-foto-editor\">&#13;<br \/>\n                                <a href=\"https:\/\/www.aa.com.tr\/tr\/p\/abonelik-talep-formu\/1001\" target=\"_blank\" style=\"font-size:12px; color:#444; text-decoration:none;\" rel=\"noopener\">&#13;<br \/>\n                                    Anadolu Ajans\u0131 web sitesinde, AA Haber Ak\u0131\u015f Sistemi (HAS) \u00fczerinden abonelere sunulan haberler, \u00f6zetlenerek yay\u0131mlanmaktad\u0131r. <b style=\"color:#1897F7\">Abonelik i\u00e7in l\u00fctfen ileti\u015fime ge\u00e7iniz.<\/b>&#13;<br \/>\n                                <\/a>&#13;<br \/>\n                            <\/span>\n                        <\/div>\n<p><script>\n\t  window.fbAsyncInit = function() {\n\t\tFB.init({\n\t\t  appId: '1855843514662870',\n\t\t  status : true, \/\/ check login status\n\t\t  cookie : true, \/\/ enable cookies to allow the server to access the session\n\t\t  xfbml  : true  \/\/ parse XFBML\n\t\t});\n\t  };<\/p>\n<p>\t  (function() {\n\t\tvar e = document.createElement('script');\n\t\te.src=\"https:\/\/connect.facebook.net\/tr_TR\/all.js\";\n\t\te.async = true;\n\t\tdocument.getElementById('fb-root').appendChild(e);\n\t  }());\n    <\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioNTech, 2023&#8217;\u00fcn \u00fc\u00e7\u00fcnc\u00fc \u00e7eyre\u011fine ili\u015fkin finansal sonu\u00e7lar\u0131n\u0131 a\u00e7\u0131klad\u0131. Buna g\u00f6re \u015firketin \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrekteki net kar\u0131, ge\u00e7en y\u0131l\u0131n ayn\u0131 d\u00f6nemine k\u0131yasla y\u00fczde 91 d\u00fc\u015ferek 160,6 milyon avroya geriledi. BioNTech, ge\u00e7en y\u0131l\u0131n temmuz-eyl\u00fcl d\u00f6neminde 1 milyar 784 milyon avro kar a\u00e7\u0131klam\u0131\u015ft\u0131. BioNTech\u2019in ABD&#8217;li orta\u011f\u0131 Pfizer veya ABD&#8217;li rakibi Moderna&#8217;n\u0131n aksine \u00fc\u00e7\u00fcnc\u00fc \u00e7eyre\u011fin sonunda kar a\u00e7\u0131klamas\u0131 dikkati \u00e7ekti. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":20593,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":[],"categories":[46],"tags":[],"_links":{"self":[{"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/posts\/20592"}],"collection":[{"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/comments?post=20592"}],"version-history":[{"count":0,"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/posts\/20592\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/media\/20593"}],"wp:attachment":[{"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/media?parent=20592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/categories?post=20592"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kraios.app\/news\/wp-json\/wp\/v2\/tags?post=20592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}